Article Details

Celltrion Healthcare receives EU CHMP positive opinion for biosimilar adalimumab, CT-P17

Retrieved on: 2020-12-11 15:45:00

Tags for this article:

Click the tags to see associated articles and topics

Celltrion Healthcare receives EU CHMP positive opinion for biosimilar adalimumab, CT-P17. View article details on hiswai:

Excerpt

CT-P17 is a recombinant human <b>monoclonal antibody</b> that contains the active ingredient adalimumab. Adalimumab is a fully human anti–tumour ...

Article found on: pipelinereview.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo